Compounds > cyc 202
Page last updated: 2024-09-04

cyc 202 and pd 0183812

cyc 202 has been researched along with pd 0183812 in 1 studies

Compound Research Comparison

Studies
(cyc 202)		Trials
(cyc 202)		Recent Studies (post-2010)
(cyc 202)		Studies
(pd 0183812)		Trials
(pd 0183812)		Recent Studies (post-2010) (pd 0183812)
9797393501

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)pd 0183812 (IC50)
G1/S-specific cyclin-E2Homo sapiens (human)0.165
Cyclin-dependent kinase 1Homo sapiens (human)0.1273
Fibroblast growth factor receptor 1Homo sapiens (human)8.62
Cyclin-dependent kinase 4Homo sapiens (human)0.082
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.1273
Cyclin-A2Homo sapiens (human)0.1478
Fibroblast growth factor receptor 2Homo sapiens (human)8.62
Fibroblast growth factor receptor 4Homo sapiens (human)8.62
Fibroblast growth factor receptor 3Homo sapiens (human)8.62
G1/S-specific cyclin-D1Homo sapiens (human)0.0975
G1/S-specific cyclin-E1Homo sapiens (human)0.1368
Cyclin-dependent kinase 2Homo sapiens (human)0.1512
G1/S-specific cyclin-D2Homo sapiens (human)0.008
G1/S-specific cyclin-D3Homo sapiens (human)0.008
Cyclin-A1Homo sapiens (human)0.209

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Li, J; Liang, C; Liu, C; Qiang, T; Ren, X; Shi, Z; Tian, L; Xing, Y1

Reviews

1 review(s) available for cyc 202 and pd 0183812

ArticleYear
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.
    Journal of medicinal chemistry, 2022, 05-12, Volume: 65, Issue:9

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Female; Humans; Pharmaceutical Preparations; Protein Kinase Inhibitors

2022